Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 18, 2026

Alamos Gold Increases Dividend by 60% to an Annual Rate of $0.16 Per Share

View original at finance.yahoo.com
Alamos Gold Increases Dividend by 60% to an Annual Rate of $0.16 Per Share Alamos Gold Inc. All amounts are in United States dollars, unless otherwise stated…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Alamos employs more than 2,400 people and is committed to the highest standards of sustainable development

    80% confidence
  • This strong production and free cash flow growth is expected to support further returns to shareholders

    80% confidence
  • Through the completion of the Phase 3+ Expansion in 2026, larger Island Gold District Expansion in 2028, and the Lynn Lake project in 2029, the Company expects to nearly double annual production to approximately one million ounces at lower costs by 2030

    80% confidence
  • The Company expects increasing free cash flow while continuing to invest in its high-return growth projects, which provide one of the strongest growth profiles in the sector

    80% confidence
  • The Company has paid dividends for 16 consecutive years during which time $463 million has been returned to shareholders through dividends and share buybacks

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com